Navigation Links
FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Date:5/21/2009

Once-Daily SAMSCA Increases Serum Sodium Levels Through Increase in Free Water Clearance

TOKYO and PRINCETON, N.J., May 21 /PRNewswire/ -- Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC) announced today that the U.S. Food and Drug Administration (FDA) has approved SAMSCA(TM) (tolvaptan) as the only oral selective vasopressin antagonist for the treatment of patients with clinically significant hypervolemic and euvolemic hyponatremia (serum sodium less than 125 mEq/L, or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction) including patients with heart failure, cirrhosis, and the syndrome of inappropriate anti-diuretic hormone (SIADH). Patients requiring urgent treatment to raise serum sodium to prevent or to treat serious neurological deficits should not be treated with SAMSCA. Additionally, it has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients. SAMSCA, an oral vasopressin V2-receptor antagonist, will be commercialized in the United States by Otsuka America Pharmaceutical, Inc. (OAPI).

Once-daily SAMSCA has been shown to significantly raise serum sodium concentrations in as early as 8 hours, and the change was maintained for 30 days. Exposure and response to SAMSCA are similar in patients with a creatinine clearance of 10-79 mL/min and in patients without renal impairment; thus no dosage adjustment is necessary. SAMSCA has not been evaluated in patients with creatinine clearance less than 10 mL/min or in patients undergoing dialysis.

"The approval of SAMSCA marks a significant milestone for Otsuka," said Taro Iwamoto, Ph.D., President and Representative Director, Otsuka Pharmaceutical Co., Ltd. "Otsuka Pharmaceutical Co., Ltd. has continued its commitment to create innovative products for cardiovascular, respiratory, digestive and infectious dise
'/>"/>

SOURCE Otsuka Pharmaceutical Co., Ltd.; Otsuka America Pharmaceutical, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Don’t have time to go ... fitness membership? Don’t know which workout equipment to use? ... order to help members achieve their heath and fitness ... an educational, caused-based wellness company, today announces the launch ... classes led by certified trainers, nutritional information and recipes ...
(Date:5/5/2015)... May 05, 2015 Major League Ultimate ... the belief that ultimate Frisbee™ is home to many ... sport that engages the world. Nike Ultimate Camps’ goal ... creating opportunities for young athletes to learn about the ... MLU the perfect fit. , The Nike Ultimate Camp ...
(Date:5/5/2015)... 05, 2015 Igantia , an ... leads an international initiative to examine key biological milestones ... human lifespan. Scientists at Igantia believe that better ... the initiation of her menstrual cycle to her transition ... aging and, ultimately, extend the lifespan. , By ...
(Date:5/5/2015)... St.Louis MO (PRWEB) May 05, 2015 ... innovative bar flavors in 2014, Walgreens introduces the Cookies ... By focusing on innovation, Extend Nutrition has continually raised ... achieved a great taste, combined with an unprecedented nutritional ... Building on this success, Extend Nutrition will launch additional ...
(Date:5/5/2015)... LENEXA, Kan. (PRWEB) May 05, 2015 ... dedicated exclusively to healthcare providers, has been retained to ... Hospital in Helena, Mont. The top executive search firm ... placed more than 900 healthcare executives into organizations. , ... psychiatric treatment facility in Montana to offer both acute ...
Breaking Medicine News(10 mins):Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 2Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 3Health News:US Sports Camps, Nike Ultimate Camps, and Major League Ultimate Host Youth Ultimate Summer Camps in Philidelphia 2Health News:Igantia Announces Digital Initiative to Decode Longevity 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4Health News:Shodair Children’s Hospital Retains B. E. Smith to Recruit New Administrator 2Health News:Shodair Children’s Hospital Retains B. E. Smith to Recruit New Administrator 3
... marketed as Revatio, study finds , TUESDAY, May 18 ... that causes progressive scarring of the lung tissue might ... Viagra, a new study finds. , The disease, called ... thick and stiff, reducing the ability to breathe. There,s ...
... life, study finds , TUESDAY, May 18 (HealthDay News) -- ... hurt feelings. Now, new research shows that a warm, caring ... growing up poor -- protection that can last well into ... with a higher risk for heart disease and other mental ...
... of the University of Helsinki, and Oncos Therapeutics, the ... next generation oncolytic viruses, published initial results from their ... The therapy program is based on scientific research at ... for ongoing clinical development. The results demonstrate ...
... the care they provide can vary widely depending upon the ... to a new RAND Corporation study. Researchers say the ... cost profiles that are being created by insurance companies in ... study provides more evidence that efforts to create physician cost ...
... will allow researchers to conduct larger, more effective studies ... in the United States. With a ... and Reinvestment Act of 2009, Cincinnati Children,s Hospital Medical ... (REGID). The first of its kind registry ...
... ... ever before. Get the facts on cancer and ways to prevent it from the Pulitzer ... ... the nation in the prevention and treatment of cancer. Truecancerfacts.com was written by Pulitzer Prize ...
Cached Medicine News:Health News:Viagra May Aid Those With Lung Fibrosis 2Health News:Viagra May Aid Those With Lung Fibrosis 3Health News:A Mother's Love Overcomes Poverty's Effect on Health 2Health News:A Mother's Love Overcomes Poverty's Effect on Health 3Health News:Oncolytic viruses mediating anti-tumor immunity in human cancer patients 2Health News:Results of physician cost profiling can vary widely, study finds 2Health News:National registry to track eosinophilic disorders 2Health News:What Doctors Won't Tell Their Patients About Cancer 2
(Date:5/5/2015)... 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ... double-blinded, placebo-controlled Phase 2 clinical trial of MM-141, ... combination with nab-paclitaxel and gemcitabine, versus nab-paclitaxel and ... cancer who have high serum levels of free ... leading cause of cancer death in ...
(Date:5/5/2015)... Mich. , May 5, 2015  InfuSystem Holdings, ... infusion pumps and related services for the U.S. healthcare ... financial results on Tuesday, May 12, 2015 after the ... a conference call for investors on Tuesday, May 12, ... quarter performance and results.  To participate in this call, ...
(Date:5/5/2015)... Mass., May 5, 2015   Cynosure, Inc. ... medical devices for aesthetic procedures and precision surgical applications ... ended March 31, 2015. First-Quarter Highlights: ... , Non-GAAP earnings of $0.15 per share; GAAP ... million at March 31, 2015 "Cynosure delivered ...
Breaking Medicine Technology:Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 2Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 3Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 2Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 3Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 5Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 6Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 7Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 8Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 9Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 10Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 11
... BEIJING, Aug. 11, 2011 /PRNewswire-Asia-FirstCall/ -- Concord Medical ... (NYSE: CCM ), the operator of ... centers in China, today announced that it has ... Healthcare ("GEHC"), through its subsidiaries General Electric International ...
... Texas, Aug. 11, 2011 ( RBC Life Sciences : ... proprietary nutritional supplements, wound care and pain management products, today ... ended June 30, 2011, compared to net sales of $7.8 ... reported net earnings of $17,000, or $0.00 per share, compared ...
Cached Medicine Technology:Concord Medical and GE Healthcare Sign MOU for Preferred Partnership in China 2RBC Life Sciences Reports Second Quarter 2011 Results 2RBC Life Sciences Reports Second Quarter 2011 Results 3
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
Hook design lifts and separates tissue for efficient dissection. Cautery action facilitates immediate control of bleeders....
This probe coagulates bleeders while suction channel with trumpet valve simultaneously evacuates smoke....
The control unit manage patient temperatures during long complex surgical procedures to help achieve optimal clinical outcomes....
Medicine Products: